NClip

Polycythemia Vera and Secondary Polycythemia

4 min read

Polycythemia Vera and Secondary Polycythemia

Key Points

  • Polycythemia is an excess-red-cell condition associated with hyperviscosity and high thrombotic risk.
  • Primary polycythemia (polycythemia vera) is linked to marrow overproduction and commonly involves JAK2V617F mutation.
  • Secondary polycythemia occurs as a response to chronic low-oxygen states.
  • Management centers on viscosity reduction, thrombosis prevention, oxygenation support, hydration, and ongoing complication surveillance.

Pathophysiology

Polycythemia is characterized by excessive red blood cell burden. In this source, abnormal blood-cell profile and increased blood viscosity are associated with reduced oxygen-carrying effectiveness, slowed blood flow, and elevated risk of thrombosis in arterial and venous circulation.

Primary polycythemia (polycythemia vera, PV) is described as marrow overproduction of red cells, with possible elevation of white cells and platelets as well. The source also describes possible genetic contribution and possible association with radiation or benzene exposure. Secondary polycythemia is described as excess red-cell production related to low-oxygen conditions such as chronic obstructive pulmonary disease.

Hyperviscosity contributes to clot events including DVT and embolic complications (for example, myocardial infarction or stroke). Ongoing hyperviscosity and cell-line abnormalities are also associated in this source with bleeding and infection risks.

Classification

  • Primary polycythemia (PV): Marrow overproduction syndrome (described as a bone marrow cancer process) with myeloproliferative behavior.
  • Secondary polycythemia: Compensatory red-cell increase due to chronic hypoxic stimuli.

Nursing Assessment

NCLEX Focus

Prioritize thrombosis and oxygenation surveillance while monitoring for bleeding and infection complications.

  • Assess for common hyperviscosity symptoms including headache, pulsatile tinnitus, vertigo, and heavy sweating.
  • Assess neurologic and vascular risk findings such as confusion, visual disturbance, transient ischemic attacks, peripheral neuropathy, and erythromelalgia.
  • Assess cardiopulmonary and thrombotic findings: dyspnea, exertional chest pain, hypertension, arterial or venous thrombosis, and pulmonary embolism risk.
  • Assess skin and bleeding findings, including pruritus, abnormal bruising, facial or hand flushing, and hematuria.
  • Monitor abdominal and psychosocial findings, including splenomegaly or hepatomegaly, weight loss, and stress or depression related to chronic illness.

Diagnostic Interpretation

  • CBC is the entry test and may show elevated RBC count, WBC count, platelets, hematocrit, and hemoglobin in PV.
  • JAK2V617F mutation testing supports confirmation; this source cites mutation presence in about 95% of PV cases.
  • Bone marrow aspiration/biopsy may be used for further characterization.

Nursing Diagnoses and Outcomes

  • Common diagnoses include risk for thrombosis, impaired gas exchange, activity intolerance, readiness for enhanced knowledge, and impaired coping.
  • Outcome targets include freedom from blood clots, freedom from excessive bleeding, and freedom from infection.

Evaluation

  • Reassess expected outcomes after each intervention cycle, updated laboratory or diagnostic result, and interprofessional care-plan review.
  • If outcomes are unmet or partially met within expected time frames, revise the care plan and intervention priorities.

Medical and Nursing Interventions

  • Therapeutic phlebotomy with plasmapheresis is used to reduce red-cell burden and blood viscosity.
  • Low-dose aspirin and, in selected cases, anticoagulation (for example, warfarin or heparin) are used for clot-risk mitigation.
  • Cytoreductive therapy (for example, hydroxyurea) and JAK2-pathway inhibition (for example, ruxolitinib) may be used in symptomatic PV.
  • Promote hydration and mobility to reduce thrombosis risk and support perfusion.
  • Monitor oxygenation and administer supplemental oxygen as indicated.
  • Teach disease process, thrombosis/bleeding warning signs, and adherence to routine phlebotomy schedule.

Hyperviscosity Risk

Rising viscosity can rapidly increase thrombotic risk; delayed recognition can lead to stroke, myocardial ischemia, or venous thromboembolism.

Self-Check

  1. How do primary and secondary polycythemia differ in cause?
  2. Why does hyperviscosity increase thrombotic risk despite high red-cell counts?
  3. Which laboratory and mutation findings help confirm polycythemia vera?

Graph View

Backlinks